| Year |
Citation |
Score |
| 1996 |
Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 37: 11-5. PMID 8543979 |
0.36 |
|
| 1995 |
Shapiro LA, Offord SJ, Ordway GA. The effect of chronic treatment with a novel aryl-piperazine antipsychotic on monoamine receptors in rat brain. Brain Research. 677: 250-6. PMID 7552250 DOI: 10.1016/0006-8993(95)00155-J |
0.52 |
|
| 1993 |
Chamberlain J, Offord SJ, Wolfe BB, Tyau LS, Wang HL, Frazer A. Potency of 5-hydroxytryptamine1a agonists to inhibit adenylyl cyclase activity is a function of affinity for the "low-affinity" state of [3H]8-hydroxy-N,N-dipropylaminotetralin ([3H]8-OH-DPAT) binding. The Journal of Pharmacology and Experimental Therapeutics. 266: 618-25. PMID 8355195 |
0.512 |
|
| 1988 |
Offord SJ, Ordway GA, Frazer A. Application of [125I]iodocyanopindolol to measure 5-hydroxytryptamine1B receptors in the brain of the rat. The Journal of Pharmacology and Experimental Therapeutics. 244: 144-53. PMID 3335996 |
0.426 |
|
| 1984 |
Offord SJ, Warwick RO. Ketanserin alters [3H]serotonin uptake and release in rat hypothalamus. European Journal of Pharmacology. 104: 379-82. PMID 6499929 DOI: 10.1016/0014-2999(84)90417-5 |
0.348 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1997 |
Gründer G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, Szymanski S, Wilson PD, Howard DR, Wong DF. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 17: 175-85. PMID 9272484 DOI: 10.1016/S0893-133X(97)00044-4 |
0.295 |
|
| 1995 |
Sanfilippo PJ, Urbanski MJ, Beers KN, Eckardt A, Falotico R, Ginsberg MH, Offord S, Press JB, Tighe J, Tomko K, Andrade-Gordon P. Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation Journal of Medicinal Chemistry. 38: 34-41. PMID 7837237 DOI: 10.1021/Jm00001A008 |
0.25 |
|
| 2017 |
Maletic V, Eramo A, Gwin K, Offord SJ, Duffy RA. The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review. Frontiers in Psychiatry. 8: 42. PMID 28367128 DOI: 10.3389/Fpsyt.2017.00042 |
0.219 |
|
| 1987 |
Offord SJ, Warwick RO. Differential effects of nialamide and clomipramine on serotonin efflux and autoreceptors. Pharmacology, Biochemistry, and Behavior. 26: 593-600. PMID 2437597 DOI: 10.1016/0091-3057(87)90171-7 |
0.201 |
|
| 1991 |
Press J, Russell R, McNally J, Rampulla R, Falotico R, Scott C, Moore J, Offord S, Tobia J. Thiophene systems. 12. Analogues of ketanserin and ritanserin as selective 5-HT2 antagonists European Journal of Medicinal Chemistry. 26: 807-813. DOI: 10.1016/0223-5234(91)90007-A |
0.177 |
|
| 2010 |
PRESS JB, RUSSELL RK, MCNALLY JJ, RAMPULLA RA, FALOTICO R, SCOTT C, MOORE JB, OFFORD SJ, TOBIA J. ChemInform Abstract: Thiophene Systems. Part 12. Analogues of Ketanserin and Ritanserin as Selective 5-HT2 Antagonists. Cheminform. 23: no-no. DOI: 10.1002/chin.199211189 |
0.176 |
|
| 2015 |
Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, Krasa HB, Johnston SS, Guiraud-Diawara A, Kamat SA, Rohman P. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric Disease and Treatment. 11: 3095-104. PMID 26719694 DOI: 10.2147/Ndt.S91917 |
0.125 |
|
| 2013 |
Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. The Journal of Clinical Psychiatry. 74: 568-75. PMID 23842008 DOI: 10.4088/JCP.12r08167 |
0.123 |
|
| 1998 |
Brunner F, Bhargava V, Howard D, Offord S. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a selective 5-HT2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers European Neuropsychopharmacology. 8: S241-S242. DOI: 10.1016/S0924-977X(98)80422-7 |
0.121 |
|
| 1989 |
Press JB, McNally JJ, Keiser JA, Offord SJ, Katz LB, Giardino E, Falotico R, Tobia AJ. Furo[3,4-d]pyrimidine-2,4-dione derivatives with antihypertensive activity. Analogues of thienopyrimidine-2,4-diones European Journal of Medicinal Chemistry. 24: 627-630. DOI: 10.1016/0223-5234(89)90033-0 |
0.118 |
|
| 1999 |
Offord SJ, Wong DF, Nyberg S. The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. Journal of Clinical Pharmacology. 17S-24S. PMID 10434243 DOI: 10.1002/j.1552-4604.1999.tb05933.x |
0.118 |
|
| 2013 |
Offord S, Wong B, Mirski D, Baker RA, Lin J. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. Journal of Medical Economics. 16: 231-9. PMID 23163287 DOI: 10.3111/13696998.2012.751025 |
0.113 |
|
| 2013 |
Bera R, Offord S, Zubek D, Lau G, Lin J, Baker RA, Karson C. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. Journal of Medical Economics. 16: 522-8. PMID 23360177 DOI: 10.3111/13696998.2013.771641 |
0.112 |
|
| 2015 |
Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in Context. 4. PMID 25834621 DOI: 10.7573/Dic.212267 |
0.111 |
|
| 2014 |
Bera R, Offord S, Zubek D, Lau G, Lin J, Karson C. Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy. Journal of Clinical Psychopharmacology. 34: 30-5. PMID 24135840 DOI: 10.1097/JCP.0b013e3182a6082a |
0.108 |
|
| 2013 |
Offord S, Lin J, Wong B, Mirski D, Baker RA. Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage. Community Mental Health Journal. 49: 625-9. PMID 23934237 DOI: 10.1007/s10597-013-9638-y |
0.095 |
|
| 2015 |
Lawson W, Johnston S, Karson C, Offord S, Docherty J, Eramo A, Kamat S, Blanchette CM, Carson W, Nasrallah HA. Racial differences in antipsychotic use: Claims database analysis of Medicaid-insured patients with schizophrenia. Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 27: 242-52. PMID 26554365 |
0.094 |
|
| 2016 |
Wilson M, Gutierrez B, Offord SJ, Blanchette CM, Eramo A, Earnshaw S, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs in Context. 5: 212273. PMID 27114739 DOI: 10.7573/Dic.212273 |
0.091 |
|
| 2016 |
Karson C, Duffy RA, Eramo A, Nylander AG, Offord SJ. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review. Neuropsychiatric Disease and Treatment. 12: 57-67. PMID 26792993 DOI: 10.2147/Ndt.S96392 |
0.091 |
|
| 2013 |
Lin J, Wong B, Offord S, Mirski D. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia. The Journal of Behavioral Health Services & Research. 40: 355-66. PMID 23579871 DOI: 10.1007/s11414-013-9329-z |
0.09 |
|
| 2013 |
Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Advances in Therapy. 30: 286-97. PMID 23483449 DOI: 10.1007/s12325-013-0016-5 |
0.088 |
|
| 2002 |
Offord SJ. The importance of a wide therapeutic window: Fexofenadine is safe and effective over a broad range of plasma concentrations Journal of Allergy and Clinical Immunology. 109: S106-S106. DOI: 10.1016/S0091-6749(02)81426-9 |
0.079 |
|
| 1999 |
Offord SJ. Is there a need for bridging studies for development of novel neuroactive drugs? Clinical Pharmacology and Therapeutics. 65: 141. |
0.072 |
|
| 2002 |
Zhou Y, Offord S, Dogan AS, Crabb AH, Wong DF. Evaluation of Antihistamine Drugs by Human [11C]doxepin Dynamic PET Studies with a Parametric Image Approach Ieee Nuclear Science Symposium and Medical Imaging Conference. 2: 1085-1091. |
0.061 |
|
| Hide low-probability matches. |